ATE216402T1 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents

Opioid-konjugate mit endogenen trägerproteinen

Info

Publication number
ATE216402T1
ATE216402T1 AT98956656T AT98956656T ATE216402T1 AT E216402 T1 ATE216402 T1 AT E216402T1 AT 98956656 T AT98956656 T AT 98956656T AT 98956656 T AT98956656 T AT 98956656T AT E216402 T1 ATE216402 T1 AT E216402T1
Authority
AT
Austria
Prior art keywords
patient
conjugates
antinociceptive
conjugate
vivo
Prior art date
Application number
AT98956656T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE216402T1 publication Critical patent/ATE216402T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT98956656T 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen ATE216402T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07
PCT/US1998/023704 WO1999024074A2 (en) 1997-11-07 1998-11-06 Novel conjugates of opioids and endogenous carriers

Publications (1)

Publication Number Publication Date
ATE216402T1 true ATE216402T1 (de) 2002-05-15

Family

ID=22057753

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen
AT01121557T ATE235513T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01121557T ATE235513T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Country Status (9)

Country Link
EP (2) EP1028971A2 (de)
JP (2) JP2001522817A (de)
AT (2) ATE216402T1 (de)
AU (3) AU1519799A (de)
CA (2) CA2301799C (de)
DE (2) DE69812727D1 (de)
ES (1) ES2173641T3 (de)
IL (1) IL135835A0 (de)
WO (3) WO1999024074A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
AU748496B2 (en) * 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1264840B1 (de) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
DK1105409T3 (da) * 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2373252C (en) * 1999-05-17 2007-08-07 Conjuchem Inc. Long lasting anti-angiogenic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
JP2004520395A (ja) 2001-02-02 2004-07-08 コンジュケム，インコーポレーテッド 長期持続性成長ホルモン放出因子誘導体
DE60226702D1 (de) 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US7927579B2 (en) 2003-01-17 2011-04-19 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
DE602005022239D1 (de) 2004-04-23 2010-08-19 Conjuchem Biotechnologies Inc Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
EP1773400A2 (de) 2004-07-08 2007-04-18 Amgen Inc. Therapeutische peptide
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US20170158599A1 (en) * 2014-07-18 2017-06-08 Joseph D. Ceccoli Compositions and methods comprising salicylates and polysalicylates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
IL135835A0 (en) 2001-05-20
WO1999024074A2 (en) 1999-05-20
WO1999024076A9 (en) 2000-06-08
DE69804974D1 (de) 2002-05-23
DE69804974T2 (de) 2002-11-07
AU1385699A (en) 1999-05-31
CA2309205A1 (en) 1999-05-20
AU1519799A (en) 1999-05-31
AU750387B2 (en) 2002-07-18
WO1999024076A2 (en) 1999-05-20
EP1007561A2 (de) 2000-06-14
CA2301799C (en) 2007-08-07
EP1028971A2 (de) 2000-08-23
WO1999024074A3 (en) 1999-08-19
WO1999024462A2 (en) 1999-05-20
ATE235513T1 (de) 2003-04-15
CA2301799A1 (en) 1999-05-20
ES2173641T3 (es) 2002-10-16
EP1007561B1 (de) 2002-04-17
AU1312799A (en) 1999-05-31
DE69812727D1 (de) 2003-04-30
JP2001522863A (ja) 2001-11-20
JP2001522817A (ja) 2001-11-20
WO1999024076A3 (en) 1999-08-19
WO1999024462A3 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
ATE235513T1 (de) Opioid-konjugate mit endogenen trägerproteinen
CA2064689A1 (en) Stabilized protein or peptide conjugates
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
AU2259392A (en) Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2066228A1 (en) Tgf-beta protein compositions for inhibition of cell proliferation
BRPI0416028A (pt) composto, conjugados do composto e de anticorpo-medicamento, composições farmacêuticas, usos dos conjugados, métodos para tratamento de cáncer, de uma doença auto-imune, de uma doença infecciosa e de um paciente, método para inibir a proliferação ou matar as células de tumor ou células cancerìgenas, método de inibição do crescimento de células de tumor, análise para detectar células de cáncer e artigo de manufatura
EP0740650A4 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
Habberfield et al. Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo
CA2107773A1 (en) Hepatoma treatment with somatostatin analogs
AU2002238687B2 (en) Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
Wright et al. Local action of parathyroid hormone (1–34) and (1–84) at the parotid gland of sheep
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
CA2326720A1 (en) Hemoglobin-haptoglobin complexes
CA2000479A1 (en) Vasopermeability-enhancing conjugates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties